Anoop Aggarwal, MD
Hematology & Oncology · Clinton, IANPI 1902864739
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $630 of the $779 with a category attached, or 80.9%. It is spread thinly across 20 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $336, 3.9 times the $85 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in IA, where the typical reported total is $603.
Across 32 payments — averaging $24.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$131
- AstraZeneca$100
- Recordati_rare_diseases_inc.$88
- Pfizer$83
- Mirati Therapeutics, Inc.$45
- Bristol Myers Squibb$38
- plus $294 from 14 others
What the payments were for
- Food & beverage$63081%
- Education$14919%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 2 | $131 |
| AstraZeneca | 1 | $100 |
| Recordati_rare_diseases_inc. | 2 | $88 |
| Pfizer | 5 | $83 |
| Mirati Therapeutics, Inc. | 2 | $45 |
| Bristol Myers Squibb | 2 | $38 |
| AbbVie | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Astellas Pharma US Inc | 2 | $33 |
| Genentech USA, Inc. | 1 | $31 |
| Merck | 2 | $30 |
| Sobi, Inc | 1 | $22 |
| Novartis | 1 | $16 |
| Verastem, Inc. | 1 | $16 |
| Taiho Oncology, Inc. | 1 | $15 |
| Gilead | 1 | $12 |
| Amgen | 1 | $12 |
| Epizyme, Inc. | 1 | $12 |
| ADC Therapeutics America, Inc. | 1 | $11 |
| Puma Biotechnology, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SARCLISA$108
How this compares
$779 in reported general payments places this provider in the 50th percentile of 75 hematology & oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 62 | $1,068,720 |
| IbrancePalbociclib | 37 | $591,892 |
| Lenalidomide | 45 | $589,758 |
| QinlockRipretinib | 13 | $358,231 |
| MekinistTrametinib Dimethyl Sulfoxide | 20 | $330,721 |
| PomalystPomalidomide | 14 | $327,961 |
| TafinlarDabrafenib Mesylate | 21 | $318,301 |
| CabometyxCabozantinib S-Malate | 12 | $274,305 |
| LumakrasSotorasib | 12 | $224,100 |
| JakafiRuxolitinib Phosphate | 21 | $213,728 |
| Abiraterone Acetate | 53 | $131,817 |
| EliquisApixaban | 140 | $99,046 |
| XareltoRivaroxaban | 51 | $31,831 |
| Imatinib Mesylate | 30 | $22,043 |
| Anastrozole | 529 | $6,296 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $38 | $1,068,72062 claims |
| PfizerIbrance, Eliquis | $83 | $690,938177 claims |
| NovartisMekinist, Tafinlar | $16 | $649,02241 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $34 | $327,96114 claims |
| AmgenLumakras | $12 | $224,10012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 75 hematology & oncology providers in Iowa.
Other hematology & oncology in Clinton
- Jorge Perez-CardonaClinton$991
- Sakeer HussainCouncil Bluffs$74K
- Usha PerepuIowa City$70K
- Umang SwamiIowa City$54K
- Umar FarooqIowa City$30K
- Brian LinkIowa City$26K
- Mark KarwalIowa City$25K
- Kartik AnandWest Des Moines$24K
- Donald WenderSioux City$22K
- Susannah FriemelDavenport$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.